Home > Dermatology > EADV 2020 > Best of the Posters > Effects IL-13 blocker improves with longer treatment duration

Effects IL-13 blocker improves with longer treatment duration

Presented By
Prof. Eric Simpson, Oregon Health & Science University, USA
EADV 2020
Phase 3, ECZTRA
Patients with atopic dermatitis (AD) who initially only showed partial response to tralokinumab showed progressive improvements when treated beyond week 16. This was the results of a pooled analysis of two phase 3 trials. In the pivotal phase 3 ECZTRA 1 (NCT03131648) and ECZTRA 2 (NCT03160885) trials in adults with moderate-to-severe AD, tralokinumab monotherapy provided significant and early improvements in clinically relevant endpoints. In both trials, significantly more patients receiving tralokinumab monotherapy than placebo achieved the primary endpoints of Investigator’s Global Assessment (IGA) 0/1, equivalent to clear or almost clear skin, and 75% improvement in Eczema Area and Severity Index (EASI 75). However, these are stringent endpoints; hence, achievement of mild disease severity (IGA 2) and a 50% improvement in EASI ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on